# Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

> **NCT06362317** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Biliary Tract Neoplasms Immunotherapy

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Lenvatinib
- **DRUG:** Gemox Chemotherapy（Gemox or GC）

## Key facts

- **NCT ID:** NCT06362317
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-06
- **Primary completion:** 2025-03-06
- **Final completion:** 2026-03-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362317, "Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06362317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*